Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of TAK-020 Solid Formulations in Healthy Volunteers
NCT02723201Phase 1Completed
- Sponsor
- Takeda
- Start
- Apr 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TAK-020 in rheumatoid arthritis (RA) and autoimmune diseases (8 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration, Time to Reach Maximum Plasma Concentration and 2 more. Started Apr 2016; status: completed.
02
Drugs
TAK-020
03
Conditions
rheumatoid arthritis (RA)autoimmune diseases
Beyond the preview
Go deeper on NCT02723201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02723201.